PRZOOM - /newswire/ -
Nottingham, United Kingdom, 2010/11/23 - Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, has signed a significant service agreement with a leading global pharmaceutical company Janssen Pharma.
The global contract will see PRECOS provide clinical tumour material, tumour model development, target validation and drug efficacy work to support Janssen's oncology drug discovery, development and biomarker programmes.
PRECOS was launched as a spin-off from the University of Nottingham, UK in August 2010. The master services agreement is a consolidation of the working relationship between the two companies, which was first established with the University of Nottingham over five years ago.
The newly formed company combines the innovation of one of the Country's leading universities with the scientific background and expertise of multi-disciplinary scientists. This places it in an optimal position to deliver specialist services, backed by significant industry expertise and cutting-edge technology, to help both pharmaceutical and biotechnology companies develop new anti-cancer drugs. PRECOS offers patient-relevant models which closely reflect the patient situation for each aspect of cancer progression encompassing pre-cancerous lesions, primary tumours and metastasis.
Chief Scientific Officer of PRECOS, Professor Sue Watson, comments: "This global contract further strengthens the long term relationship between PRECOS and Janssen and consolidates PRECOS' evolution from a primarily academic background into an ambitious commercial entity, offering significant scientific expertise and delivering highly specialist services in the development of new anti-cancer drugs."
Dr. Martin Page, Vice President, Head of Global Oncology Research, Janssen Research & Development, a division of Janssen Pharmaceutica N.V. comments:
"Our agreement with PRECOS is a natural extension of our long-standing relationship with the University of Nottingham; we look forward to continuing to build on our past successes."
About PRECOS Ltd
PRECOS Ltd. (precos.co.uk) is a flexible pre-clinical research and development service with a specific focus on oncology, with an established track record in providing expert support to direct cancer drug development projects from concept to clinic. PRECOS evaluates the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients. The PRECOS team of expert scientists assist in the selection and execution of appropriate analytical systems by a staged approach of in vitro studies, in vivo model development, subsequent in vivo mechanistic and therapeutic evaluations and post-study analyses, all conveyed with added value through specialist scientific interpretation of the data. PRECOS scientists apply cutting-edge technology and ideas to individual research programmes and delivers a flexible, tailored approach to all research objectives, whether a one-off service or a complete research programme.
PRECOS, an acronym of Pre-Clinical Oncology Services, was officially launched as a specialist business unit of the University of Nottingham (UK) in 2004. PRECOS evolved from the research expertise of the Division of Pre-clinical Oncology (formerly Academic Unit of Cancer Studies), which had successful collaborations with pharmaceutical and biotech companies in the UK, EU, US and Japan for over a decade.